TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the results of its Annual General Meeting held on June 20, 2025. Key resolutions approved include the financial budget for 2025, re-appointment of KPMG as auditors, and the election of new non-executive directors. Amendments to the Articles of Association and the abolishment of the Supervisory Committee were also approved, indicating a strategic shift in the company’s governance structure. These changes are expected to streamline operations and potentially enhance the company’s market position.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$219.74 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and production of biopharmaceutical products. The company is involved in the research and development of innovative drugs and therapies, catering primarily to the healthcare industry.
Average Trading Volume: 906,033
Technical Sentiment Signal: Buy
Current Market Cap: HK$79.89B
Find detailed analytics on 6990 stock on TipRanks’ Stock Analysis page.